Teva Pharmaceutical Industries (TEVA.TA) on Wednesday forecast mid-single digit revenue growth over the next five years as it strives to move on from its high debt and an overhang from thousands of lawsuits over its alleged role in the U.S. opioid crisis.
Israel-based Teva, the world's largest generic drugmaker, for the past five years has been hit hard by a weak U.S. generics market and stiff competition to its blockbuster multiple sclerosis drug Copaxone.
After years of negotiations, Teva on Tuesday proposed a $4.35 billion nationwide settlement - mostly cash and partly medicines - to resolve its opioid lawsuits.
